Cerus(CERS) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Cerus Corporation Announces Third Quarter 2024 Financial Results Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million CONCORD, CA, October 30, 2024 - Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended ...